Molecular Partners to Present at Upcoming Investor Conferences

Rhea-AI Summary

Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two upcoming investor conferences. The management team will engage in fireside chats at: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025 at 3:30pm ET, and 2) TD Cowen's 6th Annual Oncology Innovation Summit on May 28, 2025 at 10:00am ET. Both events will be accessible via webcast through the company's website in the investors section.

News Market Reaction – MOLN

+2.86%

1 alert

+2.86% News Effect

On the day this news was published, MOLN gained 2.86%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ:

• Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET
  

TD Cowen’s 6^th Annual Oncology Innovation Summit: Insights for ASCO & EHA:

• Fireside chat on Wednesday, May 28, 2025 beginning at 10:00am ET
  

Both events will be webcast and available on the Molecular Partners website, under the investors tab.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

FAQ

When is Molecular Partners (MOLN) presenting at the H.C. Wainwright BioConnect Conference?

Molecular Partners will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, at 3:30pm ET.

How can I watch Molecular Partners' (MOLN) presentations at the upcoming investor conferences?

Both presentations will be available via webcast on the Molecular Partners website under the investors tab.

What type of therapeutics does Molecular Partners (MOLN) develop?

Molecular Partners develops a new class of custom-built protein drugs known as DARPin therapeutics.

When is Molecular Partners (MOLN) presenting at TD Cowen's Oncology Innovation Summit?

Molecular Partners will present at TD Cowen's 6th Annual Oncology Innovation Summit on Wednesday, May 28, 2025, at 10:00am ET.